Post-COVID-19 Symptom Burden, Pulmonary Function, Exercise Capacity, and Inflammatory Markers: Findings from the CCHROMO Prospective Study

Category	Detail
Condition
Key Mechanisms	Dysregulated inflammation, autoantibodies, virus persistence, fibrotic changes, neuronal dysregulation, and emerging biomarkers.
Target Population
Care Setting

Approximately 50% of patients showed reduced inspiratory muscle strength.
One-third of patients exhibited impaired exercise capacity despite preserved spirometry.
Lower serum concentrations of CC-16 were associated with severe fatigue, indicating potential diagnostic value.
Post-COVID-19 syndrome presents with multisystemic disease and broad clinical manifestations.
Routine spirometry may be insufficient to characterize post-COVID morbidity; consider additional assessments.

Current treatment options focus on rehabilitation concepts and may include pharmacological interventions based on symptomatology.

Biomarker profiling, including CC-16, may aid in future phenotyping approaches and guide personalized treatment strategies.

Integrate symptom assessments with pulmonary function testing, exercise capacity evaluations, and mental health screenings.
Consider the heterogeneity of post-COVID manifestations in clinical assessments.

Clinical Scorecard: Post-COVID-19 Symptom Burden, Pulmonary Function, Exercise Capacity, and Inflammatory Markers: Findings from the CCHROMO Prospective Study